Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vidofludimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 20/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 8/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 2/20 | 1.00 |
| ▸ | JMJD7 | P0C870 | 1/20 | 1.00 |
| ▸ | NR4A3 | Q92570 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidofludimus SCHEMBL29352865 | 1.00 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.99 | DHODH (0.98) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL18109121 | 0.94 | DHODH (0.89) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29869156 | 0.93 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL25834765 | 0.91 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4397456 | 0.91 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL28323370 | 0.90 | DHODH (0.82) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL25839936 | 0.90 | DHODH (0.82) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL3925167 | 0.90 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4389409 | 0.90 | DHODH (0.81) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629347-B2 | Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | IMMUNIC AG (DE) | 2026-05-19 | — | — | US | claimed |
| EP-4732905-A2 | DOSAGE REGIMEN OF VIDOFLUDIMUS FOR USE IN THE TREATMENT OF CHRONIC INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | Immunic AG (DE) | 2026-04-29 | — | — | EP | claimed |
| EP-3713554-B1 | DOSAGE REGIMEN OF VIDOFLUDIMUS FOR USE IN THE TREATMENT OF CHRONIC INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | IMMUNIC AG (DE) | 2026-03-18 | — | — | EP | claimed |
| US-12433860-B2 | Treatment of multiple sclerosis comprising DHODH inhibitors | IMMUNIC AG (DE) | 2025-10-07 | — | — | US | claimed |
| US-20250120931-A1 | TREATMENT OF MULTIPLE SCHLEROSIS COMPRISING DHODH INHIBITORS | IMMUNIC AG (DE) | 2025-04-17 | — | — | US | claimed |
| US-20240180858-A1 | Treatment of Multiple Sclerosis Comprising DHODH Inhibitors | IMMUNIC AG (DE) | 2024-06-06 | — | — | US | claimed |
| US-20240100005-A1 | Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases | IMMUNIC AG (DE) | 2024-03-28 | — | — | US | claimed |
| US-11877994-B2 | Treatment of multiple sclerosis comprising DHODH inhibitors | IMMUNIC AG (DE) | 2024-01-23 | — | — | US | claimed |
| US-11877995-B2 | Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | IMMUNIC AG (DE) | 2024-01-23 | — | — | US | claimed |
| US-20230116729-A1 | COMPOUNDS AND DOSAGE REGIMEN FOR USE IN THE PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | IMMUNIC AG (DE) | 2023-04-13 | — | — | US | claimed |
| US-20140235556-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. | 2014-08-21 | — | — | US | claimed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | claimed |
| EP-2588447-A1 | NOVEL SALTS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2013-05-08 | — | — | EP | claimed |
| EP-2588446-A1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2013-05-08 | — | — | EP | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| US-20120035175-A1 | Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | 4SC AG (DE) | 2012-02-09 | — | — | US | claimed |
| US-20120029034-A1 | Novel calcium salts of Compound as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | 4SC AG (DE) | 2012-02-02 | — | — | US | claimed |
| WO-2012001151-A1 | NOVEL SALTS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2012-01-05 | — | — | WO | claimed |
| WO-2012001148-A1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2012-01-05 | — | — | WO | claimed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11877995-B2 | Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | DHODH, DHFR, DPYD | DHODH 1/4885NR4A2 1790/4885NR4A1 1597/4885 |
| US-20240100005-A1 | Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases | DHODH, DHFR, DPYD | DHODH 1/4885NR4A2 1930/4885NR4A1 1564/4885 |
| US-20230116729-A1 | COMPOUNDS AND DOSAGE REGIMEN FOR USE IN THE PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | DHODH, DHFR, DPYD | DHODH 1/4885NR4A2 1790/4885NR4A1 1597/4885 |
| US-20240180858-A1 | Treatment of Multiple Sclerosis Comprising DHODH Inhibitors | DHODH, DLD, DPYD | DHODH 1/4885NR4A2 3239/4885NR4A1 3065/4885 |
| US-20120029034-A1 | Novel calcium salts of Compound as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | PPARD, PPARG, PPARA | DHODH 3085/4885NR4A2 205/4885NR4A1 94/4885 |
| US-11877994-B2 | Treatment of multiple sclerosis comprising DHODH inhibitors | DHODH, DLD, DPYD | DHODH 1/4885NR4A2 3239/4885NR4A1 3065/4885 |
| US-20120035175-A1 | Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | ARG1, CD14, RXRG | DHODH 1882/4885NR4A2 125/4885NR4A1 22/4885 |
| US-20250120931-A1 | TREATMENT OF MULTIPLE SCHLEROSIS COMPRISING DHODH INHIBITORS | DHODH, SORD, DLD | DHODH 1/4885NR4A2 3049/4885NR4A1 3220/4885 |
| US-12433860-B2 | Treatment of multiple sclerosis comprising DHODH inhibitors | DHODH, DLD, DPYD | DHODH 1/4885NR4A2 3239/4885NR4A1 3065/4885 |
| US-12629347-B2 | Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | DHODH, FH, FAH | DHODH 1/4885NR4A2 3494/4885NR4A1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.